Cardiovascular disease: What's all the AGE/RAGE about?

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 10, Issue 1, 2010, Pages 7-15

  Barlovic, Drazenka P ^a   Thomas, Merlin C ^a   Jandeleit Dahm, Karin ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Advanced glycation; Atherosclerosis; Cardiovascular disease; Diabetes; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; FAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL MIGRATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HUMAN; INTIMA; MONOCYTE; OXIDATIVE STRESS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

EID: 77950672585     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152910790780050     Document Type: Review

References (83)

1. Garcia, M.J.; McNamara, P.M.; Gordon, T.; Kannel, W.B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes, 1974, 23, 105-111.
2. Cooper, M.E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia, 2001, 44, 1957-1972.
3. Uusitupa, M.I.; Niskanen, L.K.; Siitonen, O.; Voutilainen, E.; Pyörälä, K. 5-Year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation, 1990, 82, 27-36.
4. Gæde, P.; Lund-Andersen, H.; Parving, H.-H.; Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. N. Engl. J. Med., 2008, 358, 580-591.
5. Nakamura, Y.; Horii, Y.; Nishino, T.; Shiiki, H.; Sakaguchi, Y.; Kagoshima, T.; Dohi, K.; Makita, Z.; Vlassara, H.; Bucala, R. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol., 1993, 143, 1649-1656.
6. Kilhovd, B.K.; Juutilainen, A.; Lehto, S.; Rönnemaa, T.; Torjesen, P.A.; Birkeland, K.I.; Berg, T.J.; Hanssen, K.F.; Laakso, M. High serum levels of advanced glycation end products predict increased cardiovascular disease mortality in nondiabetic women but not in nondiabetic men: a population based 18-year follow-up study. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 815-820.
7. Kanauchi, M.; Tsujimoto, N.; Hashimoto, T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care, 2001, 24, 1620-1623.
8. Uribarri, J.; Cai, W.; Peppa, M.; Goodman, S.; Ferrrucci, L.; Striker, G.; Vlassara, H. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J. Gerontol. A. Biol. Sci. Med. Sci., 2007, 62, 427-433.
9. Gursinsky, T.; Ruhs, S.; Friess, U.; Diabate, S.; Krug, H.F.; Silber, R.E.; Simm, A. Air pollution-associated fly ash particles induce fibrotic mechanisms in primary fibroblasts. Biol. Chem., 2006, 387, 1411-1420.
10. Bierhaus, A.; Hofmann, M.A.; Ziegler, R.; Nawroth, P.P. AGE and their interaction with AGE-receptors in vascular disease and diabetes. The AGE concept. Cardiovasc. Res., 1998, 37, 586-600.
11. Degenhardt, T.P.; Thorpe, S.R.; Baynes, J.W. Chemical modification of proteins by methylglyoxal. Cell Mol. Biol., 1998, 44, 1139-1145.
12. Fu, M.X.; Wells-Knecht, K.J.; Blackledge, J.A.; Lyons, T.J.; Thorpe, S.R.; Baynes, J.W. Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes, 1994, 43, 676-683.
13. Vlassara, H.; Bucala, R. Recent progress in advanced glycation and diabetic vascular disease: role of AGE receptors. Diabetes, 1996, 45(Suppl 3), S65-S66.
14. Brownlee, M. Advanced protein glycosilation in diabetes and aging. Annu. Rev. Med., 1995, 46, 223-234.
15. Glenn, J.V.; Beattie, J.R.; Barrett, L.; Frizzell, N.; Thorpe, S.R.; Boulton, M.E.; McGarvey, J.J.; Stitt, A.W. Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging. FASEB J., 2007, 21, 3542-3552.
16. Thornalley, P. The glyoxalase system: new developments towards functional characterisation of a metabolic pathway fundamental to biological life. Biochem. J., 1990, 269, 1-11.
17. Garlick, R.L.; Mazer, J.S. The principal site of nonenzymatic glycosylation of human serum albumin in vivo. J. Biol. Chem., 1983, 258, 6142-6146.
18. Rosca, M.G.; Monnier, W.M.; Szweda, L.I.; Weiss, M.F. Alteration in renal mitochondrial respiration in response to reactive oxoaldehyde methylglyoxal. Am. J. Physiol. Renal Physiol., 2002, 283, F52-59.
19. Ahmed, N.; Thornalley, P. Peptide mapping of human serum albumin modified minimally by methylglyoxal in vitro and in vivo. Ann. N.Y. Acad. Sci., 2005, 1043, 260-266.
20. Kislinger, T.; Fu, C.; Huber, B.; Qu, W.; Taguchi, A.; Yan, S.D. et al. N-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem., 1999, 274, 31740-31749.
21. Corman, B.; Duriez, M.; Poitevin, P.; Heudes, D.; Bruneval, P.; Tedgui, A.; Levy, B.I. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc. Natl. Acad. Sci. USA, 1998, 95, 1301-1306.
22. Haitoglou, C.S.; Tsilibary, E.C.; Brownlee, M.; Charonis, A.S. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J. Biol. Chem., 1992, 267, 12404-12407.
23. Brownlee, M.; Vlassara, H.; Cerami, A. Nonenzymatic glycosilation products on collagen covalently trap low-density lipoprotein. Diabetes, 1985, 34, 938-941.
24. McRobert, E.A.; Gallicchio, M.A.; Jerums, G.; Cooper, M.E.; Bach, L.A. The amino terminal domains of ERM proteins bind advanced glycation endproducts: an interaction that may play a role in the development of of diabetic complications. J. Biol. Chem., 2003, 278, 25783-25789.
25. Febbraio, M.; Guy, E.; Silverstein RL. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 2333-2338.
26. Bucciarelli, L.G.; Wendt, T.; Qu, W.; Lu, Y.; Lalla, E.; Rong, L.L.; Goova, M.T.; Moser, B.; Kislinger, T.; Lee, D.C.; Kashyap, Y.; Stern, D.M.; Schmidt, A.M. RAGE blockade stabilises established atherosclerosis in diabetic apolipoprotein null-mice. Circulation, 2002, 106, 2827-2835.
27. Hofmann, M.A.; Drury, S.; Fu, C.; Qu, W.; Taguchi, A.; Lu, Y.; Avila, C.; Kambham, N.; Bierhaus, A.; Nawroth, P.; Neurath, M.F.; Slattery, T.; Beach, D.; McClary, J.; Nagashima, M.; Morser, J.; Stern, D.; Schmidt, A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell, 1999, 97, 889-901.
28. Chavakis, T.; Bierhaus, A.; Al-Fakhri, N; Schneider, D.; Witte, S.; Linn, T.; Nagashima, M.; Morser, J.; Arnold, B.; Preissner, K.T.; Nawroth, P.P. The pattern recognition receptor (RAGE) is a counterreceptor for leucocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med., 2003, 198, 1507-1515.
29. Neeper, M.; Schmidt, A.M.; Brett, J.; Yan, S.D.; Wang, F.; Pan, Y.C.; Elliston, K.; Stern, D.; Shaw, A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem., 1992, 267, 14998-15004.
30. Rong, L.L.; Yan, S.F.; Wendt, T.; Hans, D.; Pachydaki, S.; Bucciarelli, L.G.; Adebayo, A.; Qu, W.; Lu, Y.; Kostov, K.; Lalla, E.; Yan, S.D.; Gooch, C.; Szabolcs, M.; Trojaborg, W.; Hays, A.P.; Schmidt, A.M. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB, 2004,18, 1818-1825.
31. Huttunen, H.J.; Fages, C.; Rauvala, H. Receptor for advanced glycation end-products (RAGE) - mediated neurite outgrowth and activation of NF-kB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem., 1999, 274, 19919-19924.
32. Yan, S.D.; Schmidt, A.M.; Anderson, G.M.; Zhang, J.; Brett, J.; Zou, Y.S.; Pinsky, D.; Stern, D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem., 1994, 269, 9889-9897.
33. Basta, G.; Lazzerini, G.; Massaro, M.; Simoncini, T.; Tanganelli, P.; Fu, C.; Kislinger, T.; Stern, D.M.; Schmidt, A.M.; DeCaterina, R. Advanced glycation end-products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation, 2002, 105, 816-822.
34. Stern, D.; Yan, S.D.; Yan S.F.; Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv. Drug Deliv. Rev., 2002, 54, 1615-1625.
35. Wautier, M.P.; Chappey, O; Corda, S.; Stern, D.M.; Schmidt, A.M.; Wautier, J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab., 2001, 280, E685-694.
36. Hudson, B.I., Carter, A.M., Harja, E. et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation, 2003, 107, 2235-2243.
37. Yonekura, H.; Yamamoto, Y.; Sakurai, S.; Petrova, R.G.; Abedin, M.J.; Li, H.; Yasui, K.; Takeuchi, M.; Makita, Z.; Takasawa, S.; Okamoto, H.; Watanabe, T.; Yamamoto, H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J., 2003, 370, 1097-1109.
38. Park, L.; Raman, K.G.; Lee, K.J.; Lu, Y.; Ferran, L.J. Jr; Chow, W.S.; Stern, D.; Schmidt, A.M. Supression of accelerated diabetic atherosclerosis in diabetic apolipoprotein E-null mice. Nat. Med., 1998, 4, 1025-1031.
39. Bucala, R.; Tracey, K.J.; Cerami, A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Investig., 1991, 87, 432-438.
40. Tan, K.C.; Chow, W.S.; Ai, V.H.; Metz, C.; Bucala, R.; Lam, K.S. Advanced glycation end-products and endothelial dysfunction in type 2 diabetes. Diabetes Care, 2002, 25, 1055-1059.
41. Xu, B.; Chibber, R.; Ruggerio, D.; Kohner, E.; Ritter, J.; Ferro, A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J., 2003, 17, 1289-1291.
42. Rojas, A.; Romay, S.; Gonzalez, D.; Herrera, B.; Delgado, R.; Otero, K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosilation end products. Circ. Res., 2000, 86, E50-E54.
43. Yamagishi, S.; Fujimori, H.; Yonekura, H.; Yamamoto, Y.; Yamamoto H. Advanced glycation end-products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia, 1998, 41, 1435-1441.
44. Quehenberger, P.; Bierhaus, A.; Fasching, P.; Muellner, C.; Klevesath, M.; Hong, M.; Stier, G.; Sattler, M.; Schleicher, E.; Speiser, W.; Nawroth, P.P. Endothelin 1 transcription is controlled by nuclear factor-kB in AGE-stimulated cultured endothelial cells. Diabetes, 2000, 49, 1561-1570.
45. Bierhaus, A.; Illmer, T.; Kasper, M.; Luther, T.; Quehenberger, P.; Tritschler, H.; Wahl, P.; Ziegler, R.; Muller, M.; Nawroth, P.P. Advanced glycation end-product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation, 1997, 96, 2262-2271.
46. Basta, G.; Schmidt, A.M.; De Caterina, R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res., 2004, 63, 582-592.
47. Schmidt, A.M.; Yan, S.D.; Wautier, J.L.; Stern, D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res., 1999, 84, 489-497.
48. Wautier, J.L.; Zoukourian, C.; Chappey, O.; Wautier, M.P.; Guillausseau, P.J.; Cao, R.; Hori, O.; Stern, D.; Schmidt, A.M. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Investig., 1996, 97, 238-243.
49. Lu, M.; Kuroki, M.; Amano, S.; Tolentino, M.; Keough, K.; Kim, I.; Bucala, R.; Adamis, A.P. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J. Clin. Invest., 1998, 101, 1219-1224.
50. Sun, C.; Liang, C.; Ren, Y.; Zhen, Y.; He, Z.; Wang, H.; Tan, H.;, Pan, X.;, Wu, Z. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res. Cardiol., 2009, 104: 42-49
51. Chavakis, E.; Hain, A.; Vinci, M.; Carmona, G.; Bianchi, M.E.; Vajkoczy, P.; Zeiher, A.M.; chavakis, T.; Dimemler, S. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ. Res., 2007, 100, 204-212
52. Morigi, M.; Angioletti, S.; Imberti, B.; Donadelli, R.; Micheletti, G.; Figliuzzi, M.; Remuzzi, A.; Zoja, C.; Remuzzi, G. Leucocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycaemia in a NF-kB-dependent fashion. J. Clin. Investig., 1998, 101, 1905-1915.
53. Edelstein, D.; Brownlee, M. Mechanistic studies of advanced glycation end product inhibition by aminoguanidine. Diabetes, 1992, 41, 26-29.
54. Iwashima, Y.; Eto, M.; Hata, A.; Kaku, K.; Horiuchi, S.; Ushikubi, F.; Sano, H. Advanced glycation end-products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. Biochem. Biophys. Res. Commun., 2000, 277, 368-380.
55. Hodgkinson, C.P.; Laxton, R.C.; Patel, K.; Ye, S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 2275-2281.
56. Higashi, T.; Sano, H.; Saishoji, T.; Ikeda, K.; Jinnouchi, Y.; Kanzaki, T.; Morisaki, N.; Rauvala, H.; Shichiri, M.; Horiuchi, S. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes, 1997, 46, 463-472.
57. Monnier, V.M. Transition metals redox: reviving an old plot for diabetic vascular disease. J. Clin. Investig., 2001, 107, 799-801.
58. Paget, C.; Lecomte, M.; Ruggiero, D.; Wiernsperger, N.; Lagarde, M. Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. Free Radic. Biol. Med., 1998, 25, 121-129.
59. Coughlan, M.T.; Thorburn, D.R.; Penfold, S.A.; Laskowski, A.; Harcourt, B.E.; Sourris, K.C.; Tan, A.L.; Fukami, K.; Thallas-Bonke, V.; Nawroth, P.P.; Brownlee, M.; Bierhaus, A.; Cooper, M.E.; Forbes, J.M. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol., 2009, 20, 742-752.
60. Chen, J.; Song, M.; Yu, S.; Gao, P.; Yu, Y.; Wang, H.; Huang, L. Advanced glycation endproducts alter function and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overexpression of cell oxidant stress. Mol. Cell Biochem., 2009, 335, 137-146.
61. Esposito, C.; Gerlach, H.; Brett, J.; Stern, D.; Vlassara, H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J. Exp. Med., 1989, 170, 1387-1407.
62. Ichikawa, K.; Yoshinari, M.; Iwase, M.; Wakisaka, M.; Doi, Y.; Iino, K.; Yamamoto, M.; Fujishima, M. Advanced glycosilation end products induced tissue factor expression in human monocytelike U937 cells and incraesed tissue factor expression in monocytes from diabetic patients. Atherosclerosis, 1998,136, 281-287.
63. Chello, M.; Spadaccio, C.; Lusini, M.; Covino, E.; Blarzino, C.; De Marco, F.; Di Domenico, F.; Coccia, R. Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: posssible implications in venous graft failure. Diabetes Metab. Res. Rev., 2009, 25, 420-426.
64. Forbes, J.M.; Thorpe, S.R.; Thallas-Bonke, V.; Pete, J.; Thomas, M.C.; Deemer, E.R.; Bassal, S.; El-Osta, A.; Long, D.M.; Panagiotopoulos, S.; Jerums, G.; Osicka, T.M.; Cooper, M.E. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme -1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol., 2005, 16, 2976-2984.
65. Bolton, W.K.; Cattran, D.C.; Williams, M.E.; Adler, S.G.; Appel, G.B.; Cartwright, K.; Foiles, P.G.; Freedman, B.I.; Raskin, P.; Ratner, R.E.; Spinowitz, B.S.; Whittier, F.C.; Wuerth, J.P.; ACTION I Investigator Group. Randomised trial of an inhibitor of formation of advanced glycation of end products in diabetic nephropathy. Am. J. Nephrol., 2004, 24, 32-40.
66. Kass, D.A.; Shapiro, E.P.; Kawaguchi, M.; Capriotti, A.R.; Scuteri, A.; deGroof, R.C.; Lakatta, E.G. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation, 2001, 104, 1464-1470.
67. Forbes, J.M.; Yee, L.T.; Thallas, V.; Lassila, M.; Candido, R.; Jandeleit-Dahm, K.A.; Thomas, M.C.; Burns, W.C.; Deemer, E.K.; Thorpe, S.R.; Cooper, M.E.; Allen, T.J. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes, 2004, 53, 1813-1823.
68. Candido, R.; Forbes, J.M.; Thomas, M.C.; Thallas, V.; Dean, R.G.; Burns, W.C.; Tikellis, C.; Ritchie, R.H.; Twigg, S.M.; Cooper, M.E.; Burrell, L.M. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res., 2003, 92, 785-792.
69. Liliensiek, B.; Weigand, M.A.; Bierhaus, A.; Nicklas, W.; Kasper, M.; Hofer, S.; Plachky, J.; Gröne, H.J.; Kurschus, F.C.; Schmidt, A.M.; Yan, S.D.; Martin, E.; Schleicher, E.; Stern, D.M.; Hämmerling, G.G.; Nawroth, P.P.; Arnold, B. Receptor for advanced glycation end-products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest., 2004, 113, 1641-1650.
70. Soro-Paavonen, A.; Watson, A.M.; Li, J.; Paavonen, K.; Koitka, A.; Calkin, A.C.; Barit, D.; Coughlan, M.T.; Drew, B.G.; Lancaster, G.I.; Thomas, M.; Forbes, J.M.; Nawroth, P.P.; Bierhaus, A.; Cooper, M.E.; Jandeleit-Dahm, K.A. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes, 2008, 57, 2461-2469.
71. Park, L.; Raman , K.G.; Lee, K.J. Suppression of accelerated diabetic atherosclerosis by soluble receptor for AGE (sRAGE). Nat. Med., 1998, 4, 1025-1031.
72. Lee, K.J.; Lu, Y.; Ginsberg, M.D.; Ferran, L.J.; Stern, D.M.; Schmidt, A.M. A murine model of accelerated atherosclerosis in diabetic lDL receptor deficient mice. Circulation (Suppl), 1997, 96, I-175.
73. Wendt, B.M.; Bucciarelli, L.G.; LU, Y. Accelerated atherosclerosis and vascular inflammation develop in apoE null mice with diabetes. Circulation (suppl), 2000, 102, II-231.
74. Zheng, F.; He, C.; Cai, W.; Hattori, M.; Steffes, M.; Vlassara, H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab. Res. Rev., 2002, 18, 224-237.
75. Nathan, D.M.; Lachin, J.; Cleary, P.; Orchard, T.; Brillon, D.J.; Backlund, J.Y.; O'Leary, D.H.; Genuth, S.; Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. N. Engl. J. Med., 2003, 348, 2294-2303.
76. Stratton, I.M.; Adler, A.I.; Neil, H.A.; Matthews, D.R.; Manley, S.E.; Cull, C.A.; Hadden, D.; Turner, R.C.; Holman, R.R. on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321, 405-412.
77. Yan, S.F.; Ramasamy, R.; Bucciarelli, L.G.; Wendt, T.; Lee, L.K.; Hudson, B.I.; Stern, D.M.; Lalla, E.; DU Yan, S.; Rong, L.L.; Naka, Y.; Schmidt, A.M. RAGE and its ligands: a lasting memory in diabetic complications? Diabetes Vasc. Dis. Res., 2004, 1, 10-20.
78. El-Osta, A.; Brasacchio, D.; Yao, D.; Pocai, A.; Jones, P.L.; Roeder, R.G.; Cooper, M.E.; Brownlee, M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycaemia. J. Exp. Med., 2008, 205, 2409-2417.
79. Li, J.; Schmidt, A.M. Characterization and functional analysis of the promoter of RAGE, the Receptor for Advanced Glycation Endproducts. J. Biol. Chem., 1997, 272, 16498-16506.
80. Abizaid, A.; Kornowski, R.; Mintz, G.S.; Hong, M.K.; Abizaid, A.S.; Mehran, R.; Pichard, A.D.; Kent, K.M.; Satler, L.F.; Wu, H.; Popma, J.J.; Leon, M.B. The influence of diabetes mellitus on acute and late clinical outcome following coronary stent implantation. J. Am. Coll. Cardiol., 1998, 32, 584-589.
81. Zhou, Z.; Wang, K.; Penn, M.S.; Marso, S.P.; Lauer, M.A.; Forudi, F.; Zhou, X.; Qu, W.; Lu, Y.; Stern, D.M.; Schmidt, A.M.; Lincoff, A.M.; Topol, E.J. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation, 2003, 107, 2238-2243.
82. Seki, Y.; Kai, H.; Shibata, R.; Nagata, T.; Yasukawa, H.; Yoshimura, A.; Imaizumi, T. Role of the JAK/STAT pathway in rat carotid artery remodeling after vascular injury. Circ. Res., 2000, 87, 12-18.
83. Bierhaus, A.; Humpert, P.M.; Morcos, M.; Wendt, T.; Chavakis, T.; Arnold, B.; Stern, D.M.; Nawroth, P.P. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med., 2005, 83, 876-886.